Peter Maag, PhD, is Chief Executive Officer at Kyverna Therapeutics. Dr. Maag is a seasoned global industry executive with track record of transforming organizations and more than 20 years of executive management experience in the pharmaceutical and diagnostic industry.

Prior to joining Kyverna, Dr. Maag was Executive Chairman, President and CEO of CareDx where he built the company from a small start-up into a public company and industry-leading powerhouse in transplantation through a series of BD&L and financing transactions. Prior to joining CareDx in 2012, Dr. Maag held multiple positions at Novartis with increasing responsibilities. As President, Novartis Diagnostics, he drove growth and innovation in its blood-screening business. Prior to that, he led one of Novartis’ key affiliates as country president, Germany, and lived in a dynamically growing market as Country President, Korea. At headquarters in Switzerland, he served as the head of strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise.

Prior to joining Novartis, Dr. Maag worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. In addition to supporting various healthcare and tech companies in their growth efforts, he holds board and advisory positions at Phoenix Pharma SE, CareDx, MiroMatrix, and the Personalized Medicine Coalition. Dr. Maag received his PhD from the University of Berlin, Germany, and studied pharmaceutical sciences in Heidelberg and London.